The study confirms the importance and value of adverse drug reaction (ADR) reporting by healthcare professionals as an important source of information for postmarketing surveillance of safety of health products.
Countries with a smaller number of ADR reports used the traditional method of case-by-case review for signal detection, whereas countries with a larger number of reports use a combination of manual review and statistical methods.
Most countries surveyed indicated the importance of a quantitative signal detection algorithm to allow for systematic analysis of ADR reports. Most countries indicated that developing an algorithm is difficult given resource and/or knowledge limitations.
Introduction
Postmarketing monitoring of the safety of drugs and related health products is an integral part of pharmacovigilance (PV). By definition, PV refers to the science and activities related to the detection, assessment, understanding and prevention of adverse effects of drugs and related health products [1] . The ultimate goals of PV are the rational and safe use of health products.
Practically speaking, all drugs can cause adverse reactions. In more than 50% of approved drugs, the relatively serious adverse drug reactions (ADRs) manifest only after these drugs are marketed and used extensively in a large number of patients [2] . This is due to the intrinsic limitations of the product development process, including the inability of animal studies to fully predict human toxicity, the relatively small study sample size, short duration and narrow human subject selection in clinical trials. In addition, traditional and herbal medicines, which are perceived to be inherently safer than the more potent conventional chemical and biological pharmaceuticals, are gaining in popularity; however, these products pose different toxicological problems, such as drug-herb interactions, and the potential for adulteration with conventional medicines for unscrupulous commercial reasons [3, 4] . Consequently, all health products need to be continually monitored and assessed for safety within the context of their perceived benefits.
Other than the traditional spontaneous reporting systems, various other sources of information have been tapped for monitoring of safety information, including claims databases, use of hospital databases and sentinel site monitoring [5] . An important first step in the postmarketing surveillance process is the ability to detect safety signals from the various sources of information. A signal can be defined as reported information on a possible causal relation between an adverse event and a drug, the relation being previously unknown or incompletely documented [6] . Detection of a signal will enable the trigger of the whole cascade of PV activities, such as signal prioritization and evaluation. If the evaluation of the safety signal establishes a new ADR, this will be followed up by updating of the product's safety profile, and possibly other regulatory actions, including risk communication and other relevant risk minimization measures.
Most regulatory agencies have PV activities in place but they may be at different stages of development, especially in the area of signal detection capabilities. Many countries start out with individual reviewers conducting a manual review of the ADR reports submitted by healthcare professionals and the companies to detect safety concerns associated with marketed health products [5, 7] . However, as the number of ADR reports increase in both quantity and complexity, and start to outpace the capacity of manual review, several countries have employed statistical tools with predetermined criteria to help analyze the reports in order to more effectively detect signals of safety concerns [5, 8, 9] . The more established agencies, such as the US Food & Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA), have well-developed PV systems that utilize quantitative signal detection algorithms (QSDA) to monitor the safety of marketed health products. Association of Southeast Asian Nation (ASEAN) countries generally have a less sophisticated set up for PV. Given the exponential increase in the study and deployment of signal detection tools in recent years [5] , this paper sets out to review the status of development of PV in the ASEAN and the relevance of such tools in the ASEAN context. It also compares the findings in these countries against the more established agencies in Australia, Canada, Japan, South Korea, Switzerland, the UK and the US.
Pharmocovigilance (PV) Activities in Association of Southeast Asian Nation Countries
Singapore is situated in Southeast Asia and is an integral member state of the ASEAN, established since 1967, and has close working relations with the drug regulators in this region. The ASEAN comprises 10 member states, namely Brunei Darussalam, Cambodia, Indonesia, Lao People's Democratic Republic (PDR), Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, with more than 600 million people, linked by the ASEAN Free Trade Area and the ASEAN Single Window to create a free flow of goods and services [10] . Close cooperation has been established in many technical areas among the drug regulatory authorities in the ASEAN, including the establishment of the pharmaceutical product working groups to harmonize drug registration requirements and early drug safety alerts to one another through postmarketing surveillance [11] .
However, very few investigations have carried out an assessment of the PV landscape, focusing on ASEAN. From the literature review, the WHO Collaborating Centre for International Drug Monitoring had, in 2008, conducted a country assessment of the national PV systems. Smaller studies in Middle East and Asia have also reviewed the status of PV in their respective regions [12] [13] [14] [15] [16] . However, most of these studies focused on the status of the PV set up and none on a survey on the usefulness of QSDAs and whether these are currently employed in the different jurisdictions. In the area of signal detection, the surveys asked general questions on sources of signal detection and data generation [15] .
Given the close working relationship among the regulators, as well as the ASEAN regional harmonization initiatives to facilitate further cooperation in PV, a better understanding of the status of PV in the relevant countries, how they detect drug safety signals and whether they have developed a QSDA would be useful knowledge in guiding the development of such tools in the ASEAN. In this regard, a QSDA refers to statistical methods used to identify drug-event pairs that occur with disproportionately high frequency in spontaneous report databases with predetermined signal threshold criteria. As ASEAN regulators constantly share innovation and ideas, the findings by one member state such as Singapore may also be relevant to countries in ASEAN that have the same or similar PV set up as Singapore. This would be in line with the concept of sharing in technical innovation and facilitate the establishment of more robust and unified PV systems in the ASEAN region.
The national drug regulatory agency in Singapore has also established close working relations in the area of PV with several other well-established international drug regulatory agencies, namely the Australia Therapeutic Goods Administration, Health Canada, Japan Pharmaceuticals and Medical Devices Agency, South Korea Ministry of Food and Drug Safety, Switzerland Swissmedic, the UK MHRA and the US FDA. Confidentiality agreements have been established to collaborate and share in the area of PV. Given the close working relations that Singapore has with ASEAN countries and these seven regulatory agencies, the survey also sets out to find out whether there are any differences in the status of PV and the respective positions on QSDAs between these two groupings. This would provide some guidance and pointers for the future development of PV in ASEAN countries.
The objective of this survey was to assess the current PV status in the ASEAN region, identify sources of information for postmarketing safety monitoring, the methods used for signal detection and determine the need for a QSDA. Comparisons were also done with other drug regulatory agencies outside of the ASEAN.
Methods
A standardized questionnaire was sent out via email to all the PV centres in the 10 ASEAN member countries and seven non-ASEAN countries (please refer to the electronic supplementary material for a copy of the questionnaire). Where there was no national PV centre, the centres performing PV activities were sent a copy of the questionnaire. The latter were identified through information provided by the respective drug regulatory authorities of the country surveyed. The completed questionnaires were reviewed and subsequently followed up with emails to clarify the responses when necessary.
Prior to sending out the final version of the questionnaire, a pilot study was conducted among 10 of the regulators working at the Vigilance and Compliance Branch of the Health Sciences Authority, Singapore, to test whether they understood the phrasing of the questions in the survey form before revising and finalizing the questionnaire. The questionnaire was also sent to the Uppsala Monitoring Centre, the WHO Collaborating Centre for International Drug Monitoring, for content validity.
The questionnaire was sent out between November 2015 and June 2016. Non-responders were followed up with reminder emails and all questionnaires returned were analyzed. The questionnaire was designed to collect information on the structure, resources, functions with a focus on whether signal detection is performed, and the methods for signal detection. It aimed to capture vital information about PV in six broad areas with 22 questions:
1. An overview of the national PV programme. Data analysis consisted of descriptive statistics, including medians, and frequency distribution.
Results
All 17 countries (100%) responded to the survey. The 10 ASEAN countries were Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, while the seven non-ASEAN countries were Australia, Canada, Japan, South Korea, Switzerland, the UK and the US. In the case of Myanmar, the form was not filled as the regulator indicated in his response that the country has not started PV activities. The analysis on ASEAN countries would thus focus on the nine countries that conduct PV activities.
Overview of PV Programmes

Dedicated Centre for PV Activities
Eight ASEAN countries (94%), except Lao PDR, have a designated centre/department/unit specifically dedicated to PV. The PV activities for Lao PDR were subsumed as part of the activities under the drug regulatory agencies. All seven non-ASEAN countries (100%) have a designated centre/department/unit specifically dedicated to PV. 
Whether the PV
Year of Establishment of the PV Activities
For the ASEAN countries, the PV activities were initiated as early as 1984 (Thailand) and as recently as 2013 (Lao PDR). Considering the year of establishment and the year the countries joined the WHO monitoring programme (whichever is earlier), the median number of years among the ASEAN countries in performing PV activities was 21 (2-31 years) as at 2015.
For the non-ASEAN countries, PV activities had been carried out for a longer period of time, with a median number of years of 50 (23-55 years) as at 2015. The comparisons of national PV programmes in various countries are as shown in Table 1 .
Spontaneous ADR Reporting
ADR Reporting by Companies
For the ASEAN countries, all except two countries (namely Cambodia and Lao PDR) have a legal requirement mandating that companies marketing medicinal products in their respective countries report ADRs to the drug regulatory agency.
For the non-ASEAN countries, there is a legal requirement mandating companies marketing medicinal products in their respective countries to report ADRs to the drug regulatory agency.
ADR Reporting by Healthcare Professionals
Compared with the mandatory requirement for reporting of ADRs by companies, fewer countries mandated reporting by healthcare professionals. Four of the nine ASEAN countries (namely Indonesia, Philippines, Malaysia and Vietnam) mandated reporting by healthcare professionals. The others did not mandate ADR reporting by healthcare professionals and reporting was on a voluntary basis.
Only three of seven non-ASEAN countries mandated reporting by healthcare professionals, namely Japan, South Korea and Switzerland.
Type of Products Covered Under the ADR Monitoring Programme
The products monitored for ADRs span a wide range and include conventional pharmaceutical products, biologicals and vaccines, cosmetics, medical devices, traditional and herbal medicines, and food supplements. All of the countries surveyed monitored the safety profile of pharmaceuticals, biologics and vaccines.
Number of Years of Recording ADR Reports
The number of years of ADR reports in the records of the ASEAN countries ranged from 2 to 31 years, with a median of 17 years. The countries with the shortest and longest record keeping were for Lao PDR and Thailand, respectively, as the former has just started PV activities and Thailand was the first ASEAN country to initiate PV activities in 1984. For the non-ASEAN countries, the number of years of recording ADR reports ranged from 11 to 52 years, with a median of 44 years.
Number of ADR Reports
The total number of ADR reports that were kept in the ASEAN countries ranged from 3 to 1 million. Again, the extreme values were for Lao PDR and Thailand, for the reasons provided in the preceding paragraph. The estimated average number of reports per year received in the past 5 years (2010-2015) ranged from 3 to 50,000 for ASEAN countries. The number of reports over the last 5 years were reported to be on an upward trend for five (57%) of the countries (namely Indonesia, Malaysia, Philippines, Thailand and Vietnam) and to be approximately more or less the same for the remaining four countries (44%) [namely Brunei Darussalam, Cambodia, Lao PDR and Singapore]. Figure 1a , b show the comparisons of the number of reports in the national database in various countries. Comparatively, the non-ASEAN countries received more reports per year and have bigger databases than ASEAN 
Sources of ADR Information
All 16 countries indicated that the ADR reports from mainstream healthcare professionals such as doctors and pharmacists were one of their sources of information for monitoring of ADR reports. It was also ranked as the most important source for 12 of the 16 countries (except Australia, Canada, Indonesia and Vietnam), giving an aggregate score of 150 out of 160 (see Fig. 3 below for breakdown of the channels of reporting and ranking of importance of these channels-a score of 10 represents the most important and 1 as the least important). In this respect, Indonesia rated reports from healthcare databases, such as hospital records, and Canada rated reports obtained from intensive monitoring programmes, such as sentinel sites, as the most important sources of ADR information. Australia and Vietnam rated reviews conducted by other regulatory agencies as the most important sources of ADR information.
The other frequently used source for ADR monitoring was the ADR reports from companies or postmarketing studies conducted by these companies, and were utilized by all countries except Lao PDR. This was followed by reviews conducted by other regulatory agencies, reports obtained from intensive monitoring programmes such as sentinel sites, reports from consumers and patients, reports from healthcare databases, review of the literature, reports from other practitioners such as traditional medicine practitioners, and reports from health reimbursement organizations. Other sources of ADR information include prospective cohort studies conducted post-approval and post-mortem findings. Singapore obtained reports from the Forensic Medicine Department for ADR reporting. This department is the national mortuary that performs autopsy cases for unnatural deaths, and drug-related deaths are included as unnatural deaths in Singapore.
Management of ADR Reports and Signal Detection
System for Handling ADR Reports
All countries have a computerized system for handling of ADR reports. The most commonly used system was the Vigiflow system, an ADR report management system developed and hosted by the Uppsala Monitoring Centre [17] . Vigiflow is used by six ASEAN countries and Switzerland. Countries such as Australia, Canada, Japan, Malaysia, Singapore, Thailand, the UK and the US use either their own in-house developed databases or commercial systems, while Indonesia and Lao PDR use Excel spreadsheets. 
Detection of Signals
For the detection of safety signals, six of the ASEAN countries, namely Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia and Philippines, utilize traditional methods of signal detection, including individual case review. Singapore, Thailand and Vietnam utilize a combination of traditional and statistical analysis. All non-ASEAN countries utilize some form of statistical tools; five of the non-ASEAN countries, namely Australia, Canada, Switzerland, the UK and the US, indicate that they use a combination of traditional and statistical analysis for signal detection. The types of QSDAs or quantitative data mining tools commonly used for generating signals of disproportionate reporting are Bayesian Confidence Propagation Neural Network, Gamma Poisson Shrinker, Multi-Item Gamma Poisson Shrinker, reporting odds ratio and proportional reporting ratio [20] [21] [22] . Table 2 shows the comparison of tools for ADR report management and generation of signals of disproportionate reporting for signal detection.
Number of Local Safety Signals Detected in the Last 5 Years, and Communication of Drug Safety in the Last 10 Years
Most countries reported that they have detected local safety signals in their own countries (namely Australia, Canada, Indonesia, Lao PDR, Malaysia, Philippines, Singapore, South Korea, Switzerland, Thailand, the UK and the US). The number of signals detected in the last 5 years ranged from 1 to [100. Five countries (namely Australia, Malaysia, Switzerland, Thailand and the US) reported that they have taken drugs off their domestic market based on the strength of evidence in their ADR reports. The affected drugs include lumiracoxib, CardiaMed (noradrenaline), benzbromarone, dexfenfluramine, vulnosan, sodium camphorsulfonate, Zecuity Ò (sumatriptan iontophoretic transdermal system) and Omontys Ò (peginesatide). Eleven countries (namely Australia, Canada, Japan, Malaysia, Philippines, Singapore, South Korea, Switzerland, Thailand, the UK and the US) have issued warnings or made label changes or indication changes to the products based on the strength of evidence of the local signals in the last 10 years.
Views on a Quantitative Signal Detection
Algorithm (QSDA) 3.5.1 Importance of a QSDA All 14 agencies agreed that the development of a QSDA would help in drug signal detection and would be useful to their centres. On a Likert scale of 5 points, from strongly disagree (scale 1) to strongly agree (scale 5), eight countries, namely Canada, Lao PDR, Malaysia, Philippines, Singapore, South Korea, the UK and Vietnam, gave a rating of 'strongly agree'; six countries, namely Australia, Brunei Darussalam, Cambodia, Indonesia, Japan and Thailand, gave a rating of 'agree', and Switzerland and the US gave a rating of 'neutral'. The US FDA explained that it did not rely on a QSDA to confirm whether a signal of disproportionality was drug-related. It commented that while data mining has value, there are methodological limitations and challenges in interpreting data mining results. Swissmedic in Switzerland commented that a QSDA needs development, optimization and validation. It would need time to assess the performance of the algorithm. Health Canada uses a QSDA for ad hoc analyses and signal verification rather than for the detection of signals.
Constraints on the Development and/or Adoption of a QSDA for Drug Safety Signal Detection
The main limitation to the development of a new QSDA was the lack of knowledge and/or lack of resources cited by 12 agencies, namely Australia, Brunei Darussalam, Cambodia, Indonesia, Japan, Lao PDR, Philippines, Singapore, South Korea, Switzerland, Thailand and Vietnam (see Fig. 4 ). Three countries, namely the ASEAN countries of Brunei Darussalam, Indonesia and Lao PDR, stated that they had previously utilized a QSDA and did not find it useful, the main reason being that their number of reports was too low for a QSDA to be useful.
Discussion
The survey findings have helped establish an update of the status of PV in the nine ASEAN countries and also compared them with seven other non-ASEAN countries. As signal detection is an important first step in the cascade of postmarket PV activities, the survey has also helped identify the various channels of information sources used by the various countries for safety monitoring and the method employed for signal detection. A better understanding of the relevance of a QSDA was also obtained that has provided further impetus for Singapore to explore developing a quantitative signal detection tool that would be more relevant in its context, and possibly the ASEAN region, given the difference between ASEAN countries and the other non-ASEAN countries. While several surveys [12, 14, 16] have been performed to assess the state of PV in the different countries, including in ASEAN countries, this was the first survey that, to our knowledge, reviewed the status of PV in ASEAN countries in terms of the importance of spontaneous ADR reports, and also assessed the need for a QSDA.
This study provided an overview of the current status of PV activities in nine ASEAN countries, namely Brunei Darussalam, Cambodia, Indonesia, Lao PDR, Malaysia, Philippines, Singapore, Thailand and Vietnam. The study also included non-ASEAN countries, namely Australia, Canada, Japan, South Korea, Switzerland, the UK and the US, which Singapore has a close working relationship with. Inclusion of the latter has enabled comparison of the status of PV in ASEAN viz a viz non-ASEAN countries, and offered some insights on whether there are differences in the signal detection capabilities and perspectives of these two different groupings.
All countries have a framework for PV in place which share broad similarities in terms of general framework and structure. Our results showed that all responding countries conduct PV activities, indicating that the safety profile of marketed drugs and related health products are being routinely monitored. Regarding official structure, 15 countries, except Lao PDR, have a designated centre/ department/unit specifically dedicated to PV activities. While Lao PDR does not have a dedicated centre, PV activities are subsumed as part of drug regulatory activities. The majority of the countries (except Cambodia and Lao PDR in the ASEAN) mandated ADR reporting by companies. On the other hand, reporting by healthcare professionals is mandated only by some countries (7 of 16 countries), namely Indonesia, Philippines, Malaysia, Vietnam, Japan, South Korea and Switzerland. For example, in Switzerland, the doctors and pharmacists are mandated to report ADRs. The range of health products monitored also appeared similar. As a basic framework, all countries monitored the safety profile of pharmaceuticals, including biologics and vaccines. In addition, the majority extended the safety monitoring to other health products, such as cosmetics, health supplements, traditional/herbal medicines and medical devices. This indicates that all countries are fully aware of the gatekeeper role of ADR monitoring in public health.
Although the study was not designed specifically to compare PV development in the different countries, based on several indicators such as the number of years of experience of conducting PV activities and the number of ADR reports received per million inhabitants, it was noted that the various countries were at different stages of development of PV. The number of years in the ASEAN countries ranged from 2 to 31, compared with 23 to 55 for the non-ASEAN countries, with a median of 21 and 50 years, respectively, for the two groupings.
This observation was corroborated by a recent study by Suwankesawong et al. [16] , which reviewed the landscape of PV in ASEAN countries. The study found four of the eight ASEAN countries that participated in the survey, namely Indonesia, Malaysia, Singapore and Thailand, had functional PV systems as defined by the WHO [23] . The remaining countries (namely Cambodia, Lao PDR, Philippines and Vietnam) were assessed not to have met the minimum requirements for PV as their systems were deemed to have unclear risk communication strategies and/ or no official advisory committee on drug safety. In recent years, new sources of ADR information have emerged, such as the reporting by consumers and patients, use of hospital databases, and sentinel site monitoring [24] [25] [26] [27] . Nonetheless, it has been reported that the traditional spontaneous ADR reporting system by healthcare professionals and companies remains the primary basis for many countries to monitor and detect safety concerns of medicines in their respective jurisdictions [5, 28] . In this review, ADR reports from healthcare professionals has also been identified as the most frequently employed source of information for ADR monitoring in all the ASEAN and non-ASEAN countries. In addition, 12 countries ranked it as the most important source. All countries have also been able to detect safety signals arising from the ADR monitoring programme in their respective countries, and 11 (73%) have taken regulatory actions arising from local safety concerns, ranging from issuance of warnings, label changes or withdrawing the products from the market. These all point to the continued relevance and importance of the ADR monitoring programme in enabling actions to be taken postmarket to safeguard public health.
When comparing the volume of ADR reporting, the median of 47 ADR reports per year per million population for the nine ASEAN countries was lower than the non-ASEAN countries and the rest of the countries in the WHO database. Nonetheless, it is encouraging to note that the trend of ADR reporting is increasing in five of the ASEAN countries. Overall, approximately 70% of the countries indicated that the number of ADR reports over the last 5 years was reported to be on an upward trend. These were five of the ASEAN countries, namely Indonesia, Malaysia, Philippines, Thailand and Vietnam, and six of the non-ASEAN countries, namely Canada, Japan, South Korea, Switzerland, the UK and the US. Some countries' reports seemed to have plateaued, for which there could be several reasons. For example, in the Singapore context, there was an exponential increase in ADR reports since 2006 because of the introduction of ADR reporting via the electronic health record system known as the Critical Medical Information Store (CMIS) in the public healthcare institutions to enable healthcare professionals to enter ADRs into the CMIS at the point of care [29] . The Vigilance and Compliance Branch of the Singapore Health Sciences Authority has been receiving information on ADRs in real time via CMIS. Since then, the number of reports have remained fairly consistent, with approximately 20,000 reports received annually.
Given the importance placed on ADR reports, it would be equally important to be able to effectively analyze these ADR data as, after all, the objective of ADR monitoring is to safeguard patients and enhance safer use of medicines. In relation to this, all nine ASEAN countries and all seven non-ASEAN countries have a system for handling ADR reports. With the exception of Lao PDR, the ADR terms are coded using the WHO-ART and/or MedDRA Ò systems. Having standardized coding of the ADR reports enables systematic review and facilitates the potential application of analytical tools for data mining and signal detection, whether as is currently performed in many of the non-ASEAN countries, or for the future, as in the case of the ASEAN countries.
As signal detection is the first step in the postmarketing surveillance process to trigger the cascade of PV activities, it was useful to understand the methods used by the different countries for signal detection. Most ASEAN countries used the traditional method of case-by-case review for signal detection. In this regard, for the deployment of statistical tools for signal detection, the distinction between ASEAN and the non-ASEAN countries is more obvious. Only a small proportion of the ASEAN countries (33%) have utilized statistical methods to detect signals from ADR reports, namely Thailand, Vietnam and Singapore, compared with non-ASEAN countries (100%). This is expected as the number of reports remained relatively low for ASEAN countries in general compared with the seven non-ASEAN countries. Data mining methods are usually applied to large databases that range from hundreds of thousands to millions of records [30] . Although there is no consensus with regard to the minimum number of reports and/or drug-ADR pairs that are available in a database before quantitative signal detection techniques can be employed, data mining of small databases can result in statistical instability associated with disproportionalities [20] . Of the ASEAN countries that have employed statistical analysis for signal detection, it was noted that two countries, namely Singapore and Thailand, had total reports of 195,000 and 1 million, respectively.
In the case of those countries that have used signal detection tools, the methods employed are the existing methodologies, such as the classical frequentist method and/or the Bayesian framework. The majority of the countries have expressed that developing a new algorithm for signal detection will take considerable resources and knowledge. Nonetheless, all except two countries indicated the importance of development of a new QSDA. The US FDA stated in the questionnaire that it uses a statistical algorithm but does not rely solely on it to detect potential safety signals. There is currently no gold standard for the signal score threshold of drug-ADR pairs and there are methodological limitations and challenges in interpreting the data mining results, which demonstrates that there is a need for a more systematic analysis and detection of ADR safety concerns among regulators.
Given that Singapore is currently dedicating resources to develop a QSDA for a country with a small database, with a close working relationship among the countries, its experience will be useful for sharing with the rest of the ASEAN countries. The fact that the ASEAN countries have a computerized system to handle reports and are coded to WHO-ART may facilitate the sharing of such information. While the use of an algorithm may not be so urgent to some countries where the number of ADR reports are low, countries such as Thailand, Singapore and Malaysia, with total reports in excess of 70,000, and continually receiving more than 10,000 reports per annum, a QSDA would be highly useful. Nonetheless, given the importance of ADR reporting, a QSDA would be useful for all other ASEAN countries in times to come when their healthcare professionals become more aware of the need to detect ADRs and increase the reporting to the centre conducting PV activities and reviews.
However, practically speaking, given the current set-up of PV in the various countries and the constraints in manpower resources, the algorithm that is developed should also be relatively simple to operationalize to produce optimum outcome. The number of signals generated should also be manageable instead of churning out large numbers of signals that cannot be handled adequately and appropriately with current resources. This is especially relevant in a country such as Singapore, which is faced with the challenge of receiving a huge quantity of ADR reports beyond the capabilities of individual review by evaluators [31] .
Limitations
We have limited the survey to all ASEAN countries and seven non-ASEAN countries. While the focus was on the status of PV in ASEAN countries, it was useful and relevant to understand how the ASEAN countries compared with other non-ASEAN countries. The seven non-ASEAN countries were selected on the basis that they had confidential agreements with the Singapore Health Sciences Authority and would be open to sharing their views and data. A more comprehensive comparison would be to survey a representative sample from all other countries to make a comparison of the status of PV in the ASEAN. Nevertheless, our current study would provide a comparison between PV activities in ASEAN countries and several other countries where PV activities and regulations are better developed.
As one of the main objectives of the survey was to find out about the methods of signal detection, and also whether quantitative statistical tools were being used for signal detection in the various countries, the responses were focused on QSDAs and tools only. This may have led to the impression that the PV centres are largely in support of using quantitative tools of signal detection, when in fact if broader options were posed, for example the need for qualitative signal detection methodologies versus quantitative signal detection methodologies, the former may be picked as an option, given the smaller number of ADR reports in ASEAN countries.
There was no testing of the reliability of the questionnaire. The questions in the survey were broadly grouped into six areas designed to find out the practice, knowledge and opinions of various drug regulatory agencies, and thus a substantial portion were descriptive.
Furthermore, in order to capture the essential information for our study objectives, as a trade-off to avoid responder burden and complexity, we did not capture the types and volume of medicines used in the various countries. This information would be useful for better understanding the needs and set-up of PV activities in the various countries; however, this would require a completely different questionnaire and may cause a distraction for our current study.
Conclusions
PV is an integral part of safety monitoring of health products. All countries surveyed have PV systems in place to monitor the safe use of marketed health products. For postmarketing surveillance, it was confirmed that spontaneous ADR reports from healthcare professionals remains one of the most valuable sources for monitoring the continued safety of drugs and related products in all countries surveyed. As signal detection is the first trigger that sets off the whole cascade of PV activities in postmarketing surveillance, the study also reviewed the methods and views on signal detection. In the area of signal detection, the traditional method of case-by-case review of the spontaneous ADR reports remains an important method for signal detection for many of the ASEAN countries given the relatively lower number of ADR reports received compared with the non-ASEAN countries. As the number of ADR reports are increasing in many countries, the majority (88%) have indicated that a quantitative signal detection tool would be useful for postmarketing surveillance. It is noted that countries with large numbers of ADR reports used a combination of manual and statistical methods of quantitative signal detection to detect safety signals. It is known that signal detection is just one part of the PV process and that validation of potential signals and the ensuing PV activities are even more time-consuming and intensive. Nonetheless, a practical signal detection tool that is relatively simple to operate would be a potentially useful tool for ASEAN countries, considering the rising number of ADR reports that the countries are receiving with limited resources. While this study focused on the countries' views on the usefulness of quantitative signal detection tools, further research in the area of signal detection to find out the various trade-offs that the different countries could bear, including the ease of use of the algorithm versus the sensitivity and number of false positives, will be useful.
